News & Resources
The FDA Must Improve Communication to Patients
The American Recovery and Reinvestment Act allocated $1.1 billion dollars to coordinate research and guide investments in comparative research funded by the Act.
Pfizer Pleads Guilty to Criminally Illegal Marketing
Earlier this month, drug giant Pfizer agreed to pay a $2.3 billion penalty to settle claims over payment of kickbacks and illegal drug marketing and promotion that violated federal drug laws over an extensive period of time.
FDA’s Oversight of Post-Marketing Studies Inadequate
The Government Accountability Office (GAO) has released a new report about the FDA’s lack of post-marketing oversight in a number of the drugs which it conditionally approved.
Troubling Ghostwriting Survey Prompts New Medical Journal Policies
A survey released by The Journal of the American Medical Association (JAMA) concludes that six of the top medical journals in the U.S. published a “significant number” of ghostwritten articles in recent years, reports the NY Times.
Each year, many people in the United States are injured by defective foreign products imported into the United States.